**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 43092

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Human colorectal cancer cells frequently express IgG and display unique Ig repertoire**

Geng ZH *et al*. Repertoire of Ig expressed by human CRC cells

Zi-Han Geng, Chun-Xiang Ye, Yan Huang, Hong-Peng Jiang, Ying-Jiang Ye, Shan Wang, Yuan Zhou, Zhan-Long Shen, Xiao-Yan Qiu

**Zi-Han Geng, Xiao-Yan Qiu,** Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing 100191, China

**Zi-Han Geng, Xiao-Yan Qiu,** NHC Key Laboratory of Medical Immunology, Peking University, Beijing 100191, China

**Zi-Han Geng, Xiao-Yan Qiu,** Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing 100191, China

**Chun-Xiang Ye, Hong-Peng Jiang, Ying-Jiang Ye, Shan Wang, Zhan-Long Shen,** Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing 100044, China

**Chun-Xiang Ye, Hong-Peng Jiang, Ying-Jiang Ye, Shan Wang, Zhan-Long Shen,** Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Beijing 100044, China

**Yan Huang,** Institute of Computational Medicine, School of Artificial Intelligence, Hebei University of Technology, Tianjin 300401, China

**Yuan Zhou,** Department of Biomedical Informatics, School of Basic Medical Sciences, Center for Noncoding RNA Medicine, Peking University, Beijing 100191, China

**ORCID number:** Zi-Han Geng (0000-0002-4367-6962); Chun-Xiang Ye (0000-0001-7015-3166); Yan Huang (0000-0001-8063-6110); Hong-Peng Jiang (0000-0003-3815-5799); Ying-Jiang Ye (0000-0002-7904-3163); Shan Wang (0000-0002-4273-4307); Yuan Zhou (0000-0001-5685-066X); Zhan-Long Shen (0000-0002-4277-7067); Xiao-Yan Qiu (0000-0002-4805-8362).

**Author contributions:** Qiu XY and Shen ZL initiated and designed the research; Geng ZH and Ye CX performed all the experiments; Huang Y and Zhou Y carried out data analyzing; Jiang HP contributed in analyzing and interpreting results; Geng ZH and Qiu XY wrote the manuscript; Ye YJ, Wang S contributed in clinical diagnosis of patients; Jiang HP and Shen ZL provided clinical specimens, and clinical and pathological information.

**Supported by** Key support projects of the National Natural Science Foundation's major research program, No. 91642206; Major international cooperation projects of the National Natural Science Foundation, No. 81320108020; Beijing Natural Science Foundation, No. 7182171; Research institute fund of NHC Key Laboratory of Medical Immunology, Peking University, No. BMU2018JDJS010; and Non-profit central research institute fund of Chinese Academy of Medical Sciences, No. 2017PT31037.

**Institutional review board statement:** This work is supported by Medical Ethics Committee of Peking University People's Hospital (2018PHB 193-01).

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Xiao-Yan Qiu, MD, PhD, Doctor,** Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Xueyuan Road, Beijing 100191, China. qiuxy@bjmu.edu.cn

**Telephone:** +86-10-82805477

**Fax:** +86-10-82801149

**Received:** October 26, 2018

**Peer-review started:** October 26, 2018

**First decision:** November 14, 2018

**Revised:** January 3, 2019

**Accepted:** January 8, 2019

**Article in press:** January 9, 2019

**Published online:** March 15, 2019

**Abstract**

***BACKGROUND***

There is growing evidence proving that many human carcinomas, including colon cancer, can overexpress immunoglobulin (Ig); the non B cancer cell-derived Ig usually displayed unique V(D)J rearrangement pattern that are distinct from B cell-derived Ig. Especially, the cancer-derived Ig plays important roles in cancer initiation, progression, and metastasis. However, it still remains unclear if the colon cancer-derived Ig can display unique V(D)J pattern and sequencing, which can be used as novel target for colon cancer therapy.

***AIM***

To investigate the Ig repertoire features expressed in human colon cancer cells.

***METHODS***

Seven cancerous tissue samples of colon adenocarcinoma and corresponding noncancerous tissue samples were sorted by fluorescence-activated cell sorting using epithelial cell adhesion molecule as a marker for epithelial cells. Ig repertoire sequencing was used to analyze the expression profiles of all 5 classes of Ig heavy chains (IgH) and the Ig repertoire in colon cancer cells and corresponding normal epithelial cells.

***RESULTS***

We found that all 5 IgH classes can be expressed in both colon cancer cells and normal epithelial cells. Surprisingly, unlike the normal colonic epithelial cells that expressed 5 Ig classes, our results suggested that cancer cells most prominently express IgG. Next, we found that the usage of Ig in cancer cells caused the expression of some unique Ig repertoires compared to normal cells. Some VH segments, such as VH3-7, have been used in cancer cells, and VH3-74 was frequently present in normal epithelial cells. Moreover, compared to the normal cell-derived Ig, most cancer cell-derived Ig showed unique VHDJH patterns. Importantly, even if the same VHDJH pattern was seen in cancer cells and normal cells, cancer cell-derived IgH always displayed distinct hypermutation hot points.

***CONCLUSION***

We found that colon cancer cells could frequently express IgG and unique IgH repertoires, which may be involved in carcinogenesis of colon cancer. The unique IgH repertoire has the potential to be used as a novel target in immune therapy for colon cancer.

**Key words:** Immunoglobulin repertoire; Sequencing; Colorectal cancer; VDJ pattern; VJ pattern

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** It has been found that colon cancer cells can express immunoglobulin (Ig); however, the expression profile and features of the Ig repertoire in colon cancer cells remain unclear. Here, we first sorted colon cancer cells and normal cells from 7 patients with colon cancer. Using the Ig repertoire sequencing, we analyzed the features of the Ig heavy chain (IgH) repertoire in these cells. We found that Ig in colon cancer cells had a significant tendency to choose IgG compared to the other classes of IgH, and showed unique VHDJH patterns and somatic hypermutation hotspots, which might be potential targets for immune therapy for colon cancer.

**Citation**: Geng ZH, Ye CX, Huang Y, Jiang HP, Ye YJ, Wang S, Zhou Y, Shen ZL, Qiu XY. Human colorectal cancer cells frequently express IgG and display unique Ig repertoire. *World Journal of Gastrointestinal Oncology* 2019; 11(3): 195-207

**URL**: https://www.wjgnet.com/1948-5204/full/v11/i3/195.htm

**DOI**: https://dx.doi.org/10.4251/wjgo.v11.i3.195

**INTRODUCTION**

Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of oncological death[1]. Although using the epidermal growth factor receptor in therapies targeting colon cancer has improved the survival rate of patients, this type of cancer is still the second leading cause of deaths in men and the third in women in the United States according to cancer statistics[2-5]. Thus, more effective therapy targets need to be found.

Immunoglobulin (Ig), also classically known as an antibody, consists of two identical heavy chains (IgHs) and two identical light chains (IgLs) arranged in a roughly Y-shaped configuration[6]. Structurally, each IgH or IgL chain has its own unique viable region, which is a crucial structure that enables Igs to specifically recognize antigens, and a C-terminal conservative constant region that specifies the effector functions of the molecule[6]. The primary diversification of Ig occurs during assembly of the variable region, a process called V(D)J recombination[6]. The variable region of a heavy chain is assembled from component variables (V), diversity (D), and joining (J) gene segments and then combined with a constant region that determines the class of Ig [IgA(α), IgD(δ), IgE(ε), IgG(γ) and IgM(μ)]. Similarly, κ and λ light chains are composed of rearranged V and J gene segments[7]. After being challenged by an antigen, the variable region of Ig undergoes somatic hypermutation (SHM) that introduces point mutations into the V region antigen-binding pocket, further boosting its affinity for a particular antigen[6] (Figure 1A). Thus, Ig can initiate specific immune responses against antigens by generating a nearly infinite diversity of antigen receptors within the constraints of a finite genome[8].

Traditionally, Ig is believed to be produced only by B lymphocytes. However, our research group and others have confirmed that non-B cells[9-11], especially epithelial cancer cells (such as human lung, breast, colon, liver, cervical and oral cancer cells), can also produce Ig, including IgG, IgM and IgA[12-17]. The non B cell-derived Igs (non B-Ig) displayed several unique features, such as a conservative V(D)J usage and mutation patterns among the same lineage. Moreover, the cancer cell-derived Ig (Cancer-Ig) showed unique glycosylation modification[18,19]. Mechanistically, cancer cell-derived Ig is involved in the proliferation of cancer cells[20,21], cancer cell invasion and metastasis[19,22-24]. These findings suggest that non-B-Ig performs a different function from B-Ig. Specifically, the Cancer-Ig acts as an oncogene in cancer development; thus, there is an increased need to get a full picture of the characteristics of Cancer-Ig sequences for both basic research and clinical application.

In this study, we used immune repertoire sequencing (IR-Seq), which avoided the depth restriction of Sanger sequencing. We completed analysis of the IgH repertoire in 7 samples of epithelial cancer cells and counterpart 7 control samples from the surgical edge of resected colon tissues (taken as normal colonic epithelial cells) in patients with colorectal cancer. Our results confirmed individually biased Ig repertoires with the presence of SHM in colon cancer, which could be recognized as an indicator of their potential as neoantigen and therapeutic targets.

**MATERIALS AND METHODS**

***Patient samples***

Cancer tissue and normal tissue from the surgical edge of resected colon were obtained from patients at Peking University Peoples’ Hospital with written informed consent. The study was conducted according to an institutional review board-approved protocol and was approved by the Clinical Research Ethics Committee of Peking University Peoples’ Hospital.

***Cell sorting***

To obtain cancer cells and normal epithelial cells, tissues were first cut into small pieces (approximately 1 mm3) and washed with 1 × PBS. Epithelial cells were separated from the tissue by incubating for 1 h at 37°C with shaking in 1 × PBS supplemented with 5 mmol/L EDTA and 5 mmol/L DTT. Digested epithelial cells were then dissociated by gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) and filtered through nylon mesh. Cells were then washed in 1 × PBS with 2% fetal bovine serum (FBS) (10099141, Gibco, USA) 3 times, blocked in 1 × PBS with 5% FBS for 30 min at 4°C, and stained for 30 min at 4°C with anti-human CD19 (11-0199-41, eBioscience, USA) and anti-human epithelial cell adhesion molecule (EpCAM) (12-9326-42, eBioscience). Fluorescence-activated cell sorting (FACS) of EpCAM+ cells was then performed by FACSAria II (BD Biosciences, Franklin Lakes, NJ, USA).

***Sample preparation for IR-Seq***

Total RNA of sorted epithelial cancer cells and normal colonic epithelial cells were extracted by TRIzol Reagent (15596018, Life Technology, USA). Primer sets for IgH (iRepertoire Inc.) were used to perform two rounds of polymerase chain reaction (PCR) under the reaction conditions specified by iRepertoire® (Huntsville, AL, USA). During the first round, reverse transcription was completed and nested gene-specific primers that were complementary to V and C genes were used to introduce barcodes and sequencing primers into PCR products. The second round of PCR was carried out using communal (sequencing) primers for exponential amplification. Therefore, the entire repertoire was amplified evenly and semiquantitatively, without introducing additional amplification bias (Figure 1C). The DNA concentration of eluted PCR products were measured and 100 ng of DNA was pooled for sequencing. The following sequencing using the 2 × 250 bp Illumina MiSeq platform were performed by Novogene Corporation (Beijing, China).

***Data analysis***

iRepertoire® provided basic data analysis such as barcode demultiplexing and filtering, V(D)J alignment, and CDRs identification. For SHM analysis, filtered DNA sequences were uploaded to the IMGT/High V-Quest web-based analysis tool. The IMGT mutation analysis files were used to calculate mutant rates and find SHM hotspots. Data rendering and mapping was completed with GraphPad Prism5 software.

***Statistical analysis***

All data were analyzed with GraphPad Prism software and presented as a mean ± SD or SEM. Statistical significance was determined by the two-tailed paired or unpaired Student’s *t*-test, with significance level of *P* < 0.05, *P* < 0.01, *P* < 0.001, *P* < 0.0001, and ns, not significant (*P* > 0.05).

**RESULTS**

***IgG can be preferentially expressed in colon cancer cells***

We obtained cell samples from 7 patients, who were diagnosed with colon adenocarcinoma (Table 1). EpCAM+ epithelial cancer cells and normal epithelial cells were sorted by flow cytometry. Total RNA was extracted and reverted to cDNA. All five classes of IgH and their Ig repertoires were amplified by multiplex PCR and sequencing by IR-Seq (Figure 1A and B). We have captured the IgH expression from 5 pairs of colon cancer cells and normal cells of corresponding noncancerous tissue samples, and unpaired colon cancer cells of 2 tissue samples. We first analyzed the expression profile of IgH in the cancer cells and normal cells and found that all classes of IgH were expressed in colonic epithelial cells, but IgA and IgG appeared most frequently. Next, we compared the expression profile of IgH between 5 pairs of colon cancer cells and normal cells. We found that the normal epithelial cells could express all classes of IgH, among which IgA showed the highest frequency (5/5, mean proportion: 46.00%), followed by IgG (5/5, mean proportion: 28.35%), IgM (4/5, mean proportion: 13.77%) and IgD (4/5, mean proportion: 11.86%); however, IgE was rarely observed (3/5, mean proportion: 0.02%). Unexpectedly, the colon cancer cells mainly expressed IgG. The average percentage of IgG was significantly higher in cancer cells (86.68%) than in normal cells (28.35%) (Figure 1C and D).

***IgH repertoire in cancer cells displayed unique features***

We compared the features of IgH repertoires between cancer cells and normal epithelial cells by analyzing the complementarity determining region 3 (CDR3) pattern of the variable region, which can represent the VHDJH usage of each Ig. As with our previous findings[25], all IgH repertoires from both cancerous and normal cells showed restricted VHDJH patterns compared with the great diversity of IgH in B cells[26] (Figure 2A). However, in each case, cancer cell-derived IgH showed different IgH repertoire profiles compared to the normal epithelial cells (Table 2). Subsequently, we genetically analyzed the distribution feature of IgH expressed in cancer and normal epithelial cells. Unlike the Ig VH segments expressed in B cells that randomly distribute in the Ig chromosome, the proximal VHs, which were closer to JH segments in genomic sequence, were more frequently expressed in cancer cells than in normal cells (53.78% *vs* 38.92%) (Figure 2B), suggesting that cancer cells prefer to use these VH segments that appeared earlier in our evolution. In addition, according to the sequence characteristics, IgH can be divided into 7 families[27]. Obviously, both cancer and normal epithelial cells preferred to use VH3 segments which was consistent with B cell-expressed IgH (B-IgH)[28]; however, VH3-7 was usually used by cancer cells, and VH3-74 was frequently used by normal epithelial cells (Figure 2C and D). We also analyzed the JH usage, and found that, unlike B cell- expressed IgH, which mostly preferred JH4 andJH6, both cancer and normal epithelial cells preferred to useJH4 and JH5 (Figure 2D). The results suggest that there are diverse mechanisms of Ig gene rearrangement between B cells and colonic epithelial cells.

***VHDJH rearrangements displayed unique feature in cancer cells***

VHDJH rearrangement pattern represents the characteristic structure of each Ig heavy chain. We first explored VHDJH rearrangement patterns in each sample, and the top 10 VHDJH patterns of both cancer cells and normal cells in each case are listed in Table 2. Next, we investigated if there are some dominant VHDJH patterns shared by most cancer cells in different patient samples. Obviously, no identical VHDJH patterns were shared by cancer cells of different individual-derived IgH, but several VHDJH rearrangements, for example, VH1-8/D7-27/JH4 and VH1-18/D4-17/JH4, were found to be used by normal cells from more than one sample (Table 2). Moreover, we found that each VH of cancer-derived IgH showed unique VHDJH patterns in all 5 pairs of cancer tissues. For example, in patient-1, patient-2 and patient-3, the VH3-23 was shared by cancer cells and normal cells but was joined by totally different Ds and JHs in cancer cells compared to normal cells (Figure 3). These findings suggest that the unique VHDJH patterns may have a potential role, as neoantigens, in the development of future treatments for individual patients with colon cancer.

***IgG expressed by cancer cells displays different mutation hot points than normal epithelial cells***

According to classical theory, the variable region of IgH undergoes an extremely high rate of SHM during B cell proliferation, producing a high affinity antibody[6]. Some oncogenes are frequently mutated in cancer cells. Accordingly, we further investigated to determine if SHM also exists in IgH expressed by cancer cells. An IgH gene was defined as mutated if there were ≥ 2% mutations compared with the germline sequences. Any sequence with fewer mutations than that were considered unmutated[29]. We compared the SHM of VH3-23, which was frequently used in both cancer cells and normal cells (detected in all 6/7 cases), and found that VH3-23 in cancer cells showed significantly higher rates of mutation compared to normal cells (Figure 4A). Mutation hotspots of VH3-23 showed a significant difference between IgG expressed in cancer cells and normal cells (Figure 4B). Similarly, VH3-74/D6-19/JH4 was utilized by both cancer and normal cells, but the mutant hotspots were different (Figure 4C).

**DISCUSSION**

In this study, using Ig repertoire sequencing, we explored the expression profiles and Ig repertoires of Ig heavy chains in colon cancer cells compared to colonic epithelial cells from along the surgical margin. We found that cancer cells mainly express IgG, rather than all the Ig classes expressed by normal epithelial cells. Moreover, Ig repertoires in colon cancer cells displayed several unique features, such as VH3-7 being preferentially used. Importantly, colon cancer cell-derived Ig always displayed unique V(D)J rearrangements or mutation hot points compared to those expressed in paired normal cells. These results provide us a better understanding for the variable region characteristics of Cancer-Ig, and open a window for further studies on the role of predominant V(D)J sequences in tumorigenesis, and which might provide new targets for colon cancer therapy.

As is already known, there are 5 classes of Ig. According to our previous findings, different classes of non-B Ig display different biological activities. Under physiological condition, IgM produced by epithelial cells displays natural antibody activity[30,31], IgA expressed by normal skin epidermal cells has potential microbial-binding activity[9]. Under pathological condition, IgG and IgA are closely related to pro-tumor activity and the maintenance of stemness of cancer cells. As early as 20 years ago, Qiu *et al*[12]found that IgG was widely expressed in many types of cancer cells; the cancer-derived IgG could promote growth and survival of cancer cells. Recently, they found that an unique IgG, with a novel sialylated modification in Asn162 of CH1, was widely expressed in cancer stem cells of epithelial cancers, and promoted tumor progression via activating integrin-FAK signaling[23,24]. The expression of IgA by epithelial cancer cells of nasopharyngeal carcinoma and its participation in the evolution of cell cycle was confirmed by Zheng *et al*[15,32]. Meanwhile, they also found Igκ light chain expression in nasopharyngeal carcinoma cells regulated by NF-κB and Activator protein 1 (AP-1) pathways[33]. Chen *et al*[14], Liu *et al*[34] and Qiu *et al*[35] have confirmed that the IgG expressed by human prostate cancer, esophagus carcinoma and papillary thyroid cancer could promote tumor migration. In addition, Lee *et al*[36-38]developed the cancer-specific antibody RP215, which was initially produced using cell extracts of the human OC-3-VGH ovarian cancer cell line as antigen and specifically recognize almost all of the cancer cells but not normal cells. Moreover, the RP215 could specifically recognizes carbohydrate-associated epitope(s) localized in the variable region of IgG heavy chains expressed by cancer cells[36-38]. In this study, we found that unlike the paired normal colon epithelial cells which mainly expressed IgA, colon cancer cells mainly expressed IgG. These results suggest that IgG may be closely related to tumor progression of colon cancer.

We previously reported that Ig expressed in non-B cells had restricted VHDJH patterns, especially in some cancer cells, including colon cancer cells. We found that the colon cancer cell-derived Ig usually expressed some unique VHDJH patterns, such as the VH5-51/D3-16/JH4 and VH3-15/D3-10/JH4 by sanger sequencing[25]. NGS of the immune repertoire allows for the sequencing of millions of V(D)J sequences in parallel, and has a wide use in immune repertoire analyzing nowadays. In this study, using primers with IR-Seq that were different from our previous primers, we not only detected VH5-51/D3-16/JH4 in cancer cells of 3 samples, but more unique Ig VHDJH patterns were also seen in colon cancer cells. The cancer cells tended to utilize proximal VH genes such as VH3-7 and VH3-23, but with different Ds and JHs connected to the VH segments. Several rearrangements of the sequences were predominant in cancer cells, such as VH3-7/D3-22/JH5, VH3-23/D4-4/JH5, and VH3-13/D3-9/JH6, but there were few common advantage VHDJH rearrangements shared between different patients, increasing the importance of individualized analysis and treatment plans in the future according to the characteristics of Cancer-Ig variable regions. More importantly, the SHM sites were totally different between cancer cells and normal cells in the same individual and the same VHDJH rearrangement, such as VH3-74/D6-19/JH4, suggested that this difference contributed to the growth of cancer cells.

In summary, our results confirmed that the Cancer-Ig repertoire is biased with SHM, indicating its potency as a target in individualized treatment. Sequencing the Ig repertoire opens a window for deeper understanding and new diagnostics of colon cancer, which will hopefully help the development of new molecular targets for this disease.

**ARTICLE HIGHLIGHTS**

***Research background***

Traditionally, immunoglobulin (Ig) was believed to be only produced by B cells; however, studies from our group and others have revealed that except B cells, most of non B cells, especially the non B cancer cells, including the colon cancer cells, can frequently express Ig (non B-Ig). According to our previous findings, cancer cell-derived IgG can significantly promote cancer initiation, progression and metastasis by promoting cancer stem cell behavior. IgG overexpression predicts poor prognosis of patients with cancer. Furthermore, comparing to the B cell-derived Ig repertoire, the non B cancer cell-derived Ig displays restricted and conservative V(D)J pattern rather than diversity. However, we do not know if the colon cancer cell-derived Ig is structurally different from its counterpart normal epithelial cell-derived Ig.

***Research motivation***

In our previous work, we have found that colon cancer cells can overexpress the IgG compared to normal colonic epithelial cells, but it remains unclear if the colon cancer cell-derived Ig repertoire display unique feature compared to its counterpart normal cell-derived Ig, and whether the unique feature is potential for colon cancer target therapy.

***Research objectives***

In this study, we used Ig repertoire sequencing (IR-Seq), which allows for the sequencing of millions of V(D)J sequences in parallel, to investigate the Ig repertoire features expressed in human colon cancer cells.

***Research methods***

We first sorted EPCAM+ colon cancer cells and EPCAM+ normal colonic epithelial cells from corresponding noncancerous tissues as control. Then, using IR-Seq, the expression profile of Ig, VHDJH gene usage of Ig heavy chain (IgH) and somatic hypermutation (SHM) feature in Ig variable region were detected.

***Research results***

We surprisingly found that comparing to the control normal cells, Ig expressed by colon cancer cells had a significant tendency to choose IgG among the five Ig classes. Furthermore, unlike B-Ig that can generate nearly great diversity, the non B-Ig from either colon cancer or normal epithelial cells showed restricted VHDJH rearrangement patterns. However, comparing to normal cell-derived VHDJH rearrangement patterns, cancer cell-derived VHDJH patterns displayed unique feature, including the usage of VH, D and JH gene, and the SHM feature.

***Research conclusions***

We found that colon cancer cells could frequently express IgG and unique IgH repertoires, which may be involved in carcinogenesis of colon cancer. The unique IgH repertoire has the potential to be used as a novel target in immune therapy for colon cancer.

***Research perspectives***

These findings suggest that distinguishing the distinctive mutation sites of cancer cell-derived Ig from normal cell-derived Ig can help finding new target for precise treatment of patients with colon cancer.

**ACKNOWLEDGEMENTS**

We would like to thank Xiu-Yuan Sun (Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China), Hong-Yan Jin and Xiao-Hui Zhu (Center for Reproductive Medicine, Peking University Third Hospital;Biomedical Pioneering Innovation Center and Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, China) for assistant in cell sorting.

**REFERENCES**

1 **Arnold M**, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017; **66**: 683-691 [PMID: 26818619 DOI: 10.1136/gutjnl-2015-310912]

2 **Knijn N**, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. *Discov Med* 2010; **9**: 328-336 [PMID: 20423677]

3 **Saltz LB**, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008; **26**: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]

4 **Siegel RL**, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; **67**: 7-30 [PMID: 28055103 DOI: 10.3322/caac.21387]

5 **Siegel RL**, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017; **67**: 177-193 [PMID: 28248415 DOI: 10.3322/caac.21395]

6 **Teng G**, Papavasiliou FN. Immunoglobulin somatic hypermutation. *Annu Rev Genet* 2007; **41**: 107-120 [PMID: 17576170 DOI: 10.1146/annurev.genet.41.110306.130340]

7 **Jung D**, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. *Annu Rev Immunol* 2006; **24**: 541-570 [PMID: 16551259 DOI: 10.1146/annurev.immunol.23.021704.115830]

8 **Davis MM**, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. *Nature* 1988; **334**: 395-402 [PMID: 3043226 DOI: 10.1038/334395a0]

9 **Jiang D**, Ge J, Liao Q, Ma J, Liu Y, Huang J, Wang C, Xu W, Zheng J, Shao W, Lee G, Qiu X. IgG and IgA with potential microbial-binding activity are expressed by normal human skin epidermal cells. *Int J Mol Sci* 2015; **16**: 2574-2590 [PMID: 25625513 DOI: 10.3390/ijms16022574]

10 **Jing Z**, Deng H, Ma J, Guo Y, Liang Y, Wu R, A L, Geng Z, Qiu X, Wang Y. Expression of immunoglobulin G in human podocytes, and its role in cell viability and adhesion. *Int J Mol Med* 2018; **41**: 3296-3306 [PMID: 29512722 DOI: 10.3892/ijmm.2018.3525]

11 **Deng H**, Ma J, Jing Z, Deng Z, Liang Y, A L, Liu Y, Qiu X, Wang Y. Expression of immunoglobulin A in human mesangial cells and its effects on cell apoptosis and adhesion. *Mol Med Rep* 2018; **17**: 5272-5282 [PMID: 29393471 DOI: 10.3892/mmr.2018.8544]

12 **Qiu X**, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, Lv P, Li Z, Sun X, Wu L, Zheng J, Deng Y, Hou C, Tang P, Zhang S, Zhang Y. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. *Cancer Res* 2003; **63**: 6488-6495 [PMID: 14559841]

13 **Babbage G**, Ottensmeier CH, Blaydes J, Stevenson FK, Sahota SS. Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. *Cancer Res* 2006; **66**: 3996-4000 [PMID: 16618718 DOI: 10.1158/0008-5472.CAN-05-3704]

14 **Chen Z**, Gu J. Immunoglobulin G expression in carcinomas and cancer cell lines. *FASEB J* 2007; **21**: 2931-2938 [PMID: 17475920 DOI: 10.1096/fj.07-8073com]

15 **Zheng H**, Li M, Ren W, Zeng L, Liu HD, Hu D, Deng X, Tang M, Shi Y, Gong J, Cao Y. Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. *Mol Immunol* 2007; **44**: 2221-2227 [PMID: 17174398 DOI: 10.1016/j.molimm.2006.11.010]

16 **Lv WQ**, Peng J, Wang HC, Chen DP, Yang Y, Zhao Y, Qiu XY, Jiang JH, Li CY. Expression of cancer cell-derived IgG and extra domain A-containing fibronectin in salivary adenoid cystic carcinoma. *Arch Oral Biol* 2017; **81**: 15-20 [PMID: 28460248 DOI: 10.1016/j.archoralbio.2017.04.010]

17 **Li M**, Feng DY, Ren W, Zheng L, Zheng H, Tang M, Cao Y. Expression of immunoglobulin kappa light chain constant region in abnormal human cervical epithelial cells. *Int J Biochem Cell Biol* 2004; **36**: 2250-2257 [PMID: 15313470 DOI: 10.1016/j.biocel.2004.03.017]

18 **Liu Y**, Liu D, Wang C, Liao Q, Huang J, Jiang D, Shao W, Yin CC, Zhang Y, Lee G, Qiu X. Binding of the monoclonal antibody RP215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis. *Histopathology* 2015; **67**: 645-653 [PMID: 25753759 DOI: 10.1111/his.12686]

19 **Sheng Z**, Liu Y, Qin C, Liu Z, Yuan Y, Hu F, Du Y, Yin H, Qiu X, Xu T. IgG is involved in the migration and invasion of clear cell renal cell carcinoma. *J Clin Pathol* 2016; **69**: 497-504 [PMID: 26519488 DOI: 10.1136/jclinpath-2015-202881]

20 **Li M**, Zheng H, Duan Z, Liu H, Hu D, Bode A, Dong Z, Cao Y. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. *Cell Mol Immunol* 2012; **9**: 54-61 [PMID: 22036905 DOI: 10.1038/cmi.2011.40]

21 **Liang PY**, Li HY, Zhou ZY, Jin YX, Wang SX, Peng XH, Ou SJ. Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma. *Tumour Biol* 2013; **34**: 1783-1791 [PMID: 23483488 DOI: 10.1007/s13277-013-0717-z]

22 **Jiang C**, Huang T, Wang Y, Huang G, Wan X, Gu J. Immunoglobulin G expression in lung cancer and its effects on metastasis. *PLoS One* 2014; **9**: e97359 [PMID: 24853685 DOI: 10.1371/journal.pone.0097359]

23 **Liao Q**, Liu W, Liu Y, Wang F, Wang C, Zhang J, Chu M, Jiang D, Xiao L, Shao W, Sheng Z, Tao X, Huo L, Yin CC, Zhang Y, Lee G, Huang J, Li Z, Qiu X. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis. *Oncotarget* 2015; **6**: 40081-40094 [PMID: 26472025 DOI: 10.18632/oncotarget.5542]

24 **Tang J**, Zhang J, Liu Y, Liao Q, Huang J, Geng Z, Xu W, Sheng Z, Lee G, Zhang Y, Chen J, Zhang L, Qiu X. Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. *Cancer Lett* 2018; **430**: 148-159 [PMID: 29778566 DOI: 10.1016/j.canlet.2018.05.024]

25 **Zheng J**, Huang J, Mao Y, Liu S, Sun X, Zhu X, Ma T, Zhang L, Ji J, Zhang Y, Yin CC, Qiu X. Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. *J Biol Chem* 2009; **284**: 13610-13619 [PMID: 19293154 DOI: 10.1074/jbc.M809524200]

26 **Lee YN**, Frugoni F, Dobbs K, Tirosh I, Du L, Ververs FA, Ru H, Ott de Bruin L, Adeli M, Bleesing JH, Buchbinder D, Butte MJ, Cancrini C, Chen K, Choo S, Elfeky RA, Finocchi A, Fuleihan RL, Gennery AR, El-Ghoneimy DH, Henderson LA, Al-Herz W, Hossny E, Nelson RP, Pai SY, Patel NC, Reda SM, Soler-Palacin P, Somech R, Palma P, Wu H, Giliani S, Walter JE, Notarangelo LD. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. *Sci Immunol* 2016; **1**: eaah6109 [PMID: 28783691 DOI: 10.1126/sciimmunol.aah6109]

27 **Matsuda F**, Ishii K, Bourvagnet P, Kuma Ki, Hayashida H, Miyata T, Honjo T. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. *J Exp Med* 1998; **188**: 2151-2162 [PMID: 9841928 DOI: 10.1084/jem.188.11.2151]

28 **Nzula S**, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. *Cancer Res* 2003; **63**: 3275-3280 [PMID: 12810659]

29 **Ghiotto F**, Marcatili P, Tenca C, Calevo MG, Yan XJ, Albesiano E, Bagnara D, Colombo M, Cutrona G, Chu CC, Morabito F, Bruno S, Ferrarini M, Tramontano A, Fais F, Chiorazzi N. Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells. *Mol Med* 2011; **17**: 1188-1195 [PMID: 21785810 DOI: 10.2119/molmed.2011.00104]

30 **Hu F**, Zhang L, Zheng J, Zhao L, Huang J, Shao W, Liao Q, Ma T, Geng L, Yin CC, Qiu X. Spontaneous production of immunoglobulin M in human epithelial cancer cells. *PLoS One* 2012; **7**: e51423 [PMID: 23251529 DOI: 10.1371/journal.pone.0051423]

31 **Shao W**, Hu F, Ma J, Zhang C, Liao Q, Zhu Z, Liu E, Qiu X. Epithelial cells are a source of natural IgM that contribute to innate immune responses. *Int J Biochem Cell Biol* 2016; **73**: 19-29 [PMID: 26820901 DOI: 10.1016/j.biocel.2016.01.017]

32 **Zheng H**, Li M, Liu H, Ren W, Hu DS, Shi Y, Tang M, Cao Y. Immunoglobulin alpha heavy chain derived from human epithelial cancer cells promotes the access of S phase and growth of cancer cells. *Cell Biol Int* 2007; **31**: 82-87 [PMID: 17074514 DOI: 10.1016/j.cellbi.2006.09.009]

33 **Liu HD**, Zheng H, Li M, Hu DS, Tang M, Cao Y. Upregulated expression of kappa light chain by Epstein-Barr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cells via NF-kappaB and AP-1 pathways. *Cell Signal* 2007; **19**: 419-427 [PMID: 16979873 DOI: 10.1016/j.cellsig.2006.07.012]

34 **Liu Y**, Chen Z, Niu N, Chang Q, Deng R, Korteweg C, Gu J. IgG gene expression and its possible significance in prostate cancers. *Prostate* 2012; **72**: 690-701 [PMID: 22430367 DOI: 10.1002/pros.21476]

35 **Qiu Y**, Korteweg C, Chen Z, Li J, Luo J, Huang G, Gu J. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. *Mod Pathol* 2012; **25**: 36-45 [PMID: 21909078 DOI: 10.1038/modpathol.2011.139]

36 **Lee G**, Laflamme E, Chien CH, Ting HH. Molecular identity of a pan cancer marker, CA215. *Cancer Biol Ther* 2008; **7**: 2007-2014 [PMID: 19158477 DOI: 10.4161/cbt.7.12.6984]

37 **Lee G**. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. *Cancer Biomark* 2009; **5**: 137-142 [PMID: 19407368 DOI: 10.3233/CBM-2009-0610]

38 **Lee G**, Ge B. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. *Cancer Biomark* 2009; **5**: 177-188 [PMID: 19729827 DOI: 10.3233/CBM-2009-0102]

**P-Reviewer:** Ashley S, Cappuzzo F, Ishibashi H

**S-Editor:** Wang JL **L-Editor:** A **E-Editor:** Song H

**Specialty type:** Oncology

**Country of origin:** China

**Peer-review report classification**

**Grade A (Excellent):** A

**Grade B (Very good):** B, B


**Grade C (Good):** 0

**Grade D (Fair):** 0

**Grade E (Poor):** 0

E:\WJG\15-兼任编辑部主任\编辑稿件\2018-11-21\43092\43092\43092-Figures\1.tif

**Figure 1 Proportions of Ig classes in colon cancer cells and normal epithelial cells.** A: The process of immunoglobulin heavy chain (IgH) gene rearrangement and the structure of rearranged IgH; B: Design of the primers for the arm-polymerase chain reaction (PCR) technology used to amplify the immune repertoire. During the first round of PCR, multiple forward primers Fo (forward-out) and Fi (forward-in) were used to target V genes. The reverse primers Ro (reverse-out) and Ri (reverse-in) were targeted to the 5 classes of IgH. The Fi and Ri primers included sequencing adaptors. The second round PCR was carried out with communal primers B and A. The barcodes were in between primer A and the C gene specific primers; C: Proportions of the five IgH classes in cancer and normal cells; D: The proportion of IgG in the 5 patients. Small horizontal lines indicate the mean ± SD. Statistical significance was determined by a two-tailed unpaired Student’s *t*-test. b*P* < 0.01.



**Figure 2 The restricted VDJ patterns and distribution of immunoglobulin heavy chain in cancer and normal cells.** A: V-J-CDR3 map of immunoglobulin heavy chain (IgH) expressed in normal B cells[26], colon cancer cells and normal epithelial cells. Each rectangle represents a unique V-J-CDR3 nucleotide sequence and the size denotes its relative frequency. Colors for each rectangle are chosen randomly and, thus, do not match between plots; B: The distribution of VHs expressed in cancer and normal epithelial cells; C: The utilizations of VHs in cancer and normal epithelial cells. The order of VHs on the X-axis corresponds to its position on a chromosome; D: Utilizations of 7 VH and 6 JH families in cancer and normal cells from patients with colon cancer (red and blue columns), and B cells from peripheral blood of a healthy donor[28] (orange columns). Small horizontal lines indicate the mean ± SEM. All data comparing cancer with normal cells were determined by the two-tailed unpaired Student’s *t*-test and none of the differences were significant (*P* > 0.05). The percentage of VH and JH families in B cells (D) was derived from the data from other sources[28]; thus, statistical analysis was not performed.



**Figure 3 Different VH3-23/D/JH usages in cancer and normal cells.** The top three VH3-23/D/JH and their percentage to total VH3-23 rearrangements in cancer cells and normal epithelial cells of the first 3 patients. The same color represents the same V, D or J segment.

E:\WJG\15-兼任编辑部主任\编辑稿件\2018-11-21\43092\43092\43092-Figures\4.tif

**Figure 4 Somatic hypermutation in colon cancer and normal epithelial cells.** A: Mutation rates of VH3-23 in cancer and normal cells. Dotted lines represent the cut-off value 2%; B: Mutant positions and corresponding frequencies of VH3-23 in different patients. P1: Patient-1. P2: Patient-2. The X-axis represents the 1st to 354th nucleotides using IMGT-numbering; C: Representative mutant positions of VH3-74/D6-19/JH4 in cancer and normal cells of patient-3 compared to the germline sequence of VH3-74. Small horizontal lines indicate the mean ± SEM. All data comparing cancer with normal cells were determined by the two-tailed unpaired Student’s *t*-test. c*P*＜0.001. d*P*＜0.0001.

**Table 1 Clinical information of 7 patients with colon cancer**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID** | **Sex** | **Age** | **Clinical diagnosis** | **Tumor size (cm)** | **Differentiation** | **Vascular invasion** | **LNM** | **Distant metastasis** | **TMN** | **Histological type** | **MLH1** | **MSH2** | **MSH6** | **PMS2** |
| 1 | F | 77 | Horizontal colon cancer | 5.2 × 4.9 | Moderately and poorly differentiated | + | 0 | N/A | T4aN0M0 | Adenocarcinoma | N/A | N/A | N/A | N/A |
| 2 | F | 63 | Sigmoid colon cancer | N/A | Poorly differentiated | N/A | N/A | N/A | T3aN1bM0 | Adenocarcinoma | N/A | N/A | N/A | N/A |
| 3 | M | 77 | Right-sided colon cancer | 3 × 3 | Moderately differentiated | N/A | 0 | N/A | T4aN0M0 | Adenocarcinoma | + | + | + | - |
| 4 | F | 52 | Right-sided colon cancer | 4 × 2.5 | Well differentiated | N/A | 0 | N/A | TisN0M0 | Adenocarcinoma | + | + | + | ± |
| 5 | M | 61 | Colon cancer | 2.8 × 1.8 | Moderately differentiated | + | 1/12 | Sacrum metastasis | T4N1M1 | Adenocarcinoma | + | + | + | ± |
| 6 | M | 74 | Right-sided colon cancer | 12 × 9 × 7 | N/A | + | 15/17 | N/A | T4N3M1 | Adenocarcinoma | + | + | + | + |
| 7 | M | 89 | Right-sided colon cancer | 8.5 × 5 | Moderately differentiated | N/A | 0 | Small bowel metastasis | T4bN0M0 | Adenocarcinoma | ± | ± | ± | ± |

**Table 2 Top 10 of VHDJH rearrangement patterns in colon cancer and normal epithelial cells**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cancer** | | | | **Normal** | | | |
| **V** | **D** | **J** | **%** | **V** | **D** | **J** | **%** |
| Patient-1 | hIGHV3-13 | hIGHD3-9 | hIGHJ6 | 66.84% | hIGHV1-8 | hIGHD7-27 | hIGHJ4 | 27.25% |
| hIGHV3-30 | hIGHD6-19 | hIGHJ6 | 15.81% | hIGHV3-74 | hIGHD6-19 | hIGHJ4 | 24.71% |
| hIGHV3-30-3 | hIGHD2-8 | hIGHJ4 | 4.90% | hIGHV3-23 | hIGHD2-21 | hIGHJ5 | 18.58% |
| hIGHV5-51 | hIGHD3-16 | hIGHJ4 | 3.69% | hIGHV1-8 | hIGHD1-7 | hIGHJ3 | 6.31% |
| hIGHV3-23 | hIGHD6-13 | hIGHJ4 | 3.58% | hIGHV5-51 | hIGHD3-16 | hIGHJ4 | 5.00% |
| hIGHV3-7 | hIGHD3-9 | hIGHJ6 | 1.00% | hIGHV3-23 | hIGHD3-22 | hIGHJ6 | 2.92% |
| hIGHV3-33 | hIGHD6-19 | hIGHJ6 | 0.79% | hIGHV3-74 | hIGHD4-17 | hIGHJ4 | 2.20% |
| hIGHV3-13 | hIGHD6-13 | hIGHJ6 | 0.53% | hIGHV3-21 | hIGHD2-15 | hIGHJ5 | 1.19% |
| hIGHV3-30 | hIGHD2-8 | hIGHJ4 | 0.37% | hIGHV3-74 | hIGHD2-21 | hIGHJ5 | 1.17% |
| hIGHV3-64 | hIGHD6-19 | hIGHJ6 | 0.26% | hIGHV3-23 | hIGHD6-19 | hIGHJ4 | 1.06% |
| Patient-2 | hIGHV1-58 | hIGHD3-22 | hIGHJ4 | 43.86% | hIGHV1-18 | hIGHD4-17 | hIGHJ4 | 24.34% |
| hIGHV1-46 | hIGHD3-9 | hIGHJ4 | 18.00% | hIGHV3-11 | hIGHD5-5 | hIGHJ2 | 10.95% |
| hIGHV3-43 | hIGHD3-22 | hIGHJ4 | 10.20% | hIGHV3-74 | hIGHD6-13 | hIGHJ1 | 10.28% |
| hIGHV3-23 | hIGHD3-9 | hIGHJ4 | 6.28% | hIGHV3-9 | hIGHD6-19 | hIGHJ4 | 10.02% |
| hIGHV1-69 | hIGHD4-17 | hIGHJ3 | 5.31% | hIGHV3-23 | hIGHD3-10 | hIGHJ4 | 6.67% |
| hIGHV1-69 | hIGHD2-15 | hIGHJ5 | 3.98% | hIGHV4-4 | hIGHD3-22 | hIGHJ4 | 5.92% |
| hIGHV1-2 | hIGHD5-5 | hIGHJ4 | 2.77% | hIGHV3-15 | hIGHD3-10 | hIGHJ4 | 3.87% |
| hIGHV1-58 | hIGHD5-5 | hIGHJ4 | 1.08% | hIGHV3-49 | hIGHD6-19 | hIGHJ4 | 2.88% |
| hIGHV3-53 | hIGHD6-6 | hIGHJ4 | 1.01% | hIGHV4-59 | hIGHD3-22 | hIGHJ4 | 2.34% |
| hIGHV1-3 | hIGHD7-27 | hIGHJ6 | 0.61% | hIGHV3-53 | hIGHD6-19 | hIGHJ4 | 2.14% |
| Patient-3 | hIGHV3-23 | hIGHD4-4 | hIGHJ5 | 11.63% | hIGHV1-18 | hIGHD4-17 | hIGHJ4 | 24.71% |
| hIGHV7-4-1 | hIGHD1-26 | hIGHJ6 | 11.28% | hIGHV3-9 | hIGHD6-19 | hIGHJ4 | 11.82% |
| hIGHV3-74 | hIGHD6-6 | hIGHJ5 | 11.16% | hIGHV3-11 | hIGHD5-5 | hIGHJ2 | 10.21% |
| hIGHV3-23 | hIGHD3-16 | hIGHJ5 | 6.15% | hIGHV3-74 | hIGHD6-13 | hIGHJ1 | 9.42% |
| hIGHV3-48 | hIGHD4-4 | hIGHJ4 | 5.29% | hIGHV3-23 | hIGHD3-10 | hIGHJ4 | 6.20% |
| hIGHV2-5 | hIGHD5-12 | hIGHJ4 | 5.16% | hIGHV4-4 | hIGHD3-22 | hIGHJ4 | 5.93% |
| hIGHV1-69 | hIGHD5-5 | hIGHJ4 | 4.83% | hIGHV3-15 | hIGHD3-10 | hIGHJ4 | 4.39% |
| hIGHV3-23 | hIGHD3-22 | hIGHJ5 | 4.18% | hIGHV4-59 | hIGHD3-22 | hIGHJ4 | 2.78% |
| hIGHV3-53 | hIGHD5-12 | hIGHJ4 | 2.14% | hIGHV3-49 | hIGHD6-19 | hIGHJ4 | 2.50% |
| hIGHV3-11 | hIGHD2-15 | hIGHJ4 | 2.07% | hIGHV3-53 | hIGHD6-19 | hIGHJ4 | 2.06% |
| Patient-4 | hIGHV3-7 | hIGHD3-22 | hIGHJ5 | 57.78% | hIGHV3-74 | hIGHD2-8 | hIGHJ5 | 88.00% |
| hIGHV3-48 | hIGHD3-22 | hIGHJ5 | 13.33% | hIGHV1-8 | hIGHD7-27 | hIGHJ4 | 4.00% |
| hIGHV1-58 | hIGHD3-22 | hIGHJ4 | 11.11% | hIGHV3-74 | hIGHD6-19 | hIGHJ4 | 2.00% |
| hIGHV3-43 | hIGHD3-22 | hIGHJ4 | 6.67% | hIGHV3-74 | hIGHD2-21 | hIGHJ5 | 2.00% |
| hIGHV3-23 | hIGHD3-9 | hIGHJ4 | 4.44% | hIGHV3-23 | hIGHD2-21 | hIGHJ5 | 2.00% |
| hIHGV3-74 | hIGHD2-8 | hIGHJ5 | 2.22% | hIGHV3-74 | hIGHD5-5 | hIGHJ6 | 2.00% |
| hIGHV3-21 | hIGHD3-22 | hIGHJ5 | 2.22% | N/A | | | |
| hIHGV1-46 | - | hIGHJ4 | 2.22% | N/A | | | |
| Patient-5 | hIHGV3-7 | hIHGD3-22 | hIHGJ5 | 65.96% | hIGHV3-7 | hIGHD3-22 | hIGHJ5 | 60.00% |
| hIHGV3-21 | hIHGD3-22 | hIHGJ5 | 4.26% | hIGHV1-8 | hIGHD7-27 | hIGHJ4 | 12.31% |
| hIHGV3-74 | hIHGD6-6 | hIHGJ5 | 4.26% | hIGHV1-8 | hIGHD1-7 | hIGHJ3 | 6.15% |
| hIHGV7-4-1 | hIHGD1-26 | hIHGJ6 | 4.26% | hIGHV3-23 | hIGHD2-21 | hIGHJ5 | 4.62% |
| hIHGV3-48 | hIHGD3-22 | hIHGJ5 | 4.26% | hIGHV3-74 | hIGHD6-19 | hIGHJ4 | 4.62% |
| hIHGV3-48 | hIHGD4-4 | hIHGJ4 | 4.26% | hIGHV3-74 | hIGHD2-8 | hIGHJ4 | 3.08% |
| hIHGV3-11 | hIHGD2-15 | hIHGJ4 | 2.13% | hIGHV5-51 | hIGHD3-16 | hIGHJ4 | 1.54% |
| hIHGV3-33 | hIHGD3-22 | hIHGJ5 | 2.13% | hIGHV3-9 | hIGHD2-21 | hIGHJ5 | 1.54% |
| hIHGV3-23 | hIHGD3-22 | hIHGJ5 | 2.13% | hIGHV3-33 | hIGHD3-22 | hIGHJ5 | 1.54% |
| hIHGV3-72 | hIHGD1-7 | hIHGJ6 | 2.13% | hIGHV3-74 | hIGHD6-25 | hIGHJ4 | 1.54% |
| Patient-6 | hIGHV1-8 | hIGHD6-13 | hIGHJ5 | 44.32% | N/A | | | |
| hIGHV4-61 | hIGHD3-16 | hIGHJ6 | 16.60% |
| hIGHV1-8 | hIGHD3-10 | hIGHJ5 | 14.34% |
| hIGHV3-23 | hIGHD3-22 | hIGHJ3 | 11.74% |
| hIGHV1-8 | hIGHD7-27 | hIGHJ4 | 6.00% |
| hIGHV3-23 | hIGHD2-21 | hIGHJ5 | 4.57% |
| hIGHV3-74 | hIGHD6-19 | hIGHJ4 | 0.96% |
| hIGHV4-61 | hIGHD2-21 | hIGHJ6 | 0.17% |
| hIGHV3-74 | hIGHD3-22 | hIGHJ3 | 0.13% |
| hIGHV1-8 | hIGHD3-16 | hIGHJ5 | 0.13% |
| Patient-7 | hIGHV3-7 | hIGHD3-22 | hIGHJ5 | 80.95% | N/A | | | |
| hIGHV3-21 | hIGHD3-22 | hIGHJ5 | 1.28% |
| hIGHV3-33 | hIGHD3-22 | hIGHJ5 | 0.92% |
| hIGHV3-23 | hIGHD4-4 | hIGHJ5 | 0.92% |
| hIGHV7-4-1 | hIGHD1-26 | hIGHJ6 | 0.92% |
| hIGHV3-23 | hIGHD3-22 | hIGHJ5 | 0.73% |
| hIGHV3-48 | hIGHD3-22 | hIGHJ5 | 0.73% |
| hIGHV2-5 | hIGHD5-12 | hIGHJ4 | 0.73% |
| hIGHV3-48 | hIGHD4-4 | hIGHJ4 | 0.55% |
| hIGHV3-48 | hIGHD3-22 | hIGHJ5 | 0.55% |